Latest Conference Articles

September 9th 2021, 8:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

September 9th 2021, 8:24pm

IASLC World Conference on Lung Cancer

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

September 9th 2021, 7:46pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

September 9th 2021, 7:38pm

International Myeloma Society Annual Meeting

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

September 9th 2021, 7:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

September 9th 2021, 7:07pm

IASLC World Conference on Lung Cancer

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.

September 9th 2021, 7:03pm

International Myeloma Society Annual Meeting

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

September 9th 2021, 6:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

September 9th 2021, 6:06pm

International Myeloma Society Annual Meeting

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

September 9th 2021, 5:59pm

International Myeloma Society Annual Meeting

Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.

September 9th 2021, 5:24pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

September 9th 2021, 5:15pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

September 9th 2021, 4:35pm

International Myeloma Society Annual Meeting

Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.

September 9th 2021, 3:42pm

IASLC World Conference on Lung Cancer

Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.

September 9th 2021, 3:30pm

IASLC World Conference on Lung Cancer

Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.

September 8th 2021, 10:28pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

September 8th 2021, 10:00pm

IASLC World Conference on Lung Cancer

The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.

September 8th 2021, 9:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

September 8th 2021, 8:52pm

IASLC World Conference on Lung Cancer

Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

September 8th 2021, 7:55pm

IASLC World Conference on Lung Cancer

Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.